HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ridogrel

structure given in first source; has thromboxane A2 synthetase inhibition & thromboxane A2/prostaglandin endoperoxide receptor blocking activity
Also Known As:
5-((((3-pyridinyl)(3-(trifluoromethyl)phenyl)methylene)amino)oxy)pentanoic acid; R 68,070; R 68070; R 70416; R-68070; R-70416; Pentanoic acid, 5-(((3-pyridinyl(3-(trifluoromethyl)phenyl)methylene)amino)oxy)-, (E)-
Networked: 34 relevant articles (7 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Carty, E: 3 articles (05/2002 - 06/2000)
2. Rampton, D S: 3 articles (05/2002 - 06/2000)
3. Larivière, Richard: 2 articles (08/2004 - 03/2003)
4. Lebel, Marcel: 2 articles (08/2004 - 03/2003)
5. Moreau, Claudia: 2 articles (08/2004 - 03/2003)
6. Rodrigue, Marie-Eve: 2 articles (08/2004 - 03/2003)
7. Baby, Krishnaprasad: 1 article (01/2020)
8. Maity, Swastika: 1 article (01/2020)
9. Mehta, Chetan H: 1 article (01/2020)
10. Nayak, Usha Y: 1 article (01/2020)

Related Diseases

1. Ulcerative Colitis
2. Thrombosis (Thrombus)
08/01/1991 - "This study reveals 1) a differential efficacy of TXA2 synthase inhibition, singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism, depending on the extent of the vessel wall lesion triggering thrombosis and the size of the thrombus required to obstruct the vascular lumen and 2) a significant synergism in preventing occlusive thrombosis of extensively damaged coronary arteries between strong TXA2 synthase inhibition and comparatively modest TXA2/prostaglandin endoperoxide receptor antagonism with ridogrel."
08/01/1991 - "However, such an occlusive thrombus formation was significantly reduced by combined TXA2 synthase/prostaglandin endoperoxide receptor inhibition (5 mg/kg i.v. ridogrel; time to occlusion greater than 300 minutes, n = 7; incidence of occlusion within 300 minutes, one of seven experiments; p less than 0.05). "
01/01/1993 - "Fifty minutes after occlusive thrombus formation, the animals received intravenously (i) saline (S); (ii) ketanserin, 0.3 mg/kg (K), a 5-HT2-receptor antagonist; (iii) ridogrel, either at a low dose 0.3 mg/kg (R 0.3), exerting single TXA2 synthase inhibition; or (iv) at 5 mg/kg (R 5), exerting additional TXA2/PGH2-receptor antagonism; or (v) the combination of either dose of ridogrel with ketanserin. "
01/01/1991 - "These observations demonstrate (1) a transfer of prostaglandin endoperoxides from the vessel wall to the platelets to reinforce thrombus formation in vivo; (2) the antithrombotic potential of combined TxA2 synthetase inhibition plus TxA2/prostaglandin endoperoxide receptor blockade with ridogrel."
08/01/1991 - "By contrast, occlusive thrombosis on deep vascular damage elicited by intraluminal stimulation (150-microA anodal constant current) in nonpreconstricted canine coronary arteries (time to occlusion, 237.1 +/- 13.9 minutes; n = 7; incidence of occlusion within 300 minutes, six of seven experiments) was not affected by platelet cyclooxygenase inhibition (5 mg/kg i.v. acetylsalicylic acid; n = 7), single TXA2 synthase inhibition (1.25 mg/kg i.v. ridogrel; n = 7), or single TXA2/prostaglandin endoperoxide receptor antagonism (10 mg/kg + 10 mg/kg/hr i.v. sulotroban for 300 minutes; n = 5). "
3. Crohn Disease (Crohn's Disease)
4. Necrosis
5. Hypertension (High Blood Pressure)

Related Drugs and Biologics

1. Thromboxanes
2. prostaglandin endoperoxide receptor
3. Magnesium Sulfate (Sulfate, Magnesium)
4. Colforsin
5. Atrasentan
6. Thromboxane A2 (A2, Thromboxane)
7. Aspirin (Acetylsalicylic Acid)
8. pitavastatin (itavastatin)
9. rosoxacin
10. Thromboxane-A Synthase

Related Therapies and Procedures

1. Therapeutics
2. Enema (Enemas)
3. Catheters
4. Ligation
5. Intraperitoneal Injections